There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atossa Therapeutics (ATOS – Research Report) and Karuna Therapeutics (KRTX – Research Report) with bullish sentiments.
Atossa Therapeutics (ATOS)
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $0.67, close to its 52-week low of $0.50.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of
Atossa Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Karuna Therapeutics (KRTX)
Berenberg Bank analyst Caroline Palomeque maintained a Buy rating on Karuna Therapeutics today and set a price target of $282.00. The company’s shares closed last Tuesday at $161.33.
According to TipRanks.com, Palomeque is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $273.57, representing a 50.0% upside. In a report issued on March 20, Bank of America Securities also maintained a Buy rating on the stock with a $306.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATOS:
- Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
- Atossa to Present at the Sidoti Small-Cap Virtual Conference
- Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
- Atossa Therapeutics doses first patient in Phase 2 EVANGELINE study
- Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen
